SARS-CoV-2 and COVID-19 Research

This study shows that DNA aptamer nanomaterials can protect against diverse SARS-CoV-2 variants through respiratory mucosal administration, offering broad neutralization and superior protection compared to monoclonal antibodies.

This study uses super-resolution microscopy to reveal the nanoscale organization of SARS-CoV-2 replication organelles, showing distinct vgRNA and dsRNA clusters and changes over infection stages.

This paper develops a biophysical model to predict the fitness of SARS-CoV-2 variants based on RBD binding thermodynamics and epistatic interactions.

This paper evaluates the AVX/COVID-12 vaccine's ability to activate T cells and bind antibodies from vaccinated individuals and SARS-CoV-2-infected patients.

This study shows that p38-MAPK is essential for SARS-CoV-2 replication, as its inhibition reduces viral growth and its activation supports RNA/protein synthesis without affecting viral entry or budding.

This study reveals that SARS-CoV-2 nucleocapsid protein hyperphosphorylation by GSK-3 involves a complex, cooperative priming mechanism rather than simple sequential phosphorylation.

This study evaluates a hybrid vaccine combining influenza and SARS-CoV-2 antigens in rhesus macaques, showing strong immune responses and protection against SARS-CoV-2 infection.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

This study shows that SARS-CoV-2 ORF8 protein modulates lung inflammation and disease severity in mice by affecting macrophage infiltration and function.

This study evaluates the antiviral efficacy of GS-5245 against multiple SARS-CoV-2 variants and other coronaviruses, showing broad in vitro activity and protective effects in animal models.

This paper develops a volatile oil formula from traditional Chinese medicine that inhibits SARS-CoV-2 by targeting multiple viral and host proteins in cultured cells.

The paper validates repurposed drugs against SARS-CoV-2 using stem cell-derived cardiomyocyte and nasal epithelium models, confirming fluvoxamine's antiviral efficacy in combination with other drugs.

This paper develops a mutant ACE2 that neutralizes SARS-CoV-2 in vivo through aerosolized delivery, demonstrating its protective effect in a mouse model.

This study investigates the virological properties of the SARS-CoV-2 KP.2 variant, finding it has higher viral fitness and immune resistance compared to JN.1, contributing to its rapid spread.

The paper uses a pseudotyped virus infection assay to assess how SARS-CoV-2 variants interact with ACE2 receptor variants across species, revealing structural and compatibility shifts.

This study compares neutralizing antibody titers in human and hamster sera against SARS-CoV-2 variants using a live-virus neutralization assay, finding hamster sera show higher reactivity.

This study investigates the interaction between SARS-CoV-2 Nsp9 and nanobody 2NSP90 using NMR spectroscopy and molecular dynamics simulations, revealing stoichiometry and epitope details.

This study uses high-throughput screening to identify small molecule inhibitors that block coronavirus entry, finding a novel broad-spectrum antiviral.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

This study uses deep mutational scanning to analyze the SARS-CoV-2 spike fusion peptide, identifying mutations affecting viral entry and antibody resistance.

The paper compares glycosylation and structural changes between SARS-CoV-2 Omicron and D614G spike proteins, finding increased surface accessibility in Omicron due to altered glycosylation.

The paper compares antibody responses from individuals with XBB reinfection and those vaccinated with WSK-V102C, showing the vaccine induces stronger neutralization against SARS-CoV-2 variants including JN.1 and BA.2.87.1.

The paper describes the scalable production and purification of SARS-CoV-2 nucleocapsid proteins in E. coli and evaluates their use in ELISA assays.

This study investigates the virological traits of the SARS-CoV-2 BA.2.87.1 lineage, finding it efficiently enters human cells but is more sensitive to antibody neutralization than JN.1.

This study develops a live-attenuated SARS-CoV-2 vaccine candidate, BK2102, which induces long-term immunity and is safe in animal models.

This paper models viral resistance emergence in SARS-CoV-2 treated with anti-spike monoclonal antibodies, showing that target cell replenishment mechanisms can explain high viral rebounds.

This study identifies an ACE2-independent pathway for sarbecovirus entry in human cells, mediated by TMPRSS2-related proteases and linked to reduced antibody neutralization.

The paper evaluates neutralising antibody titres against SARS-CoV-2 variant JN.1 using live-virus microneutralisation assays in vaccinated individuals, finding higher titres in monovalent vaccine recipients.

This study compares two plant-derived Hsp90 adjuvants, showing that rNbHsp90.3 induces stronger neutralizing antibodies and different cytokine profiles than rAtHsp81.2 when used with SARS-CoV2 RBD antigen.